Kidney disease treatment is undergoing a fundamental transformation, driven by breakthroughs in regenerative medicine and smarter clinical trial design. Researchers are now growing functional kidneys from patients' own cells in laboratory settings, while artificial intelligence is helping accelerate the discovery of new therapies and streamline how clinical trials are conducted. These advances could reshape care for the millions of people living with chronic kidney disease (CKD) and those waiting for transplants.

What Are Lab-Grown Kidneys and When Will They Be Available?

One of the most promising developments on the horizon is the creation of artificial kidneys grown from a patient's own cells. These lab-engineered organs are designed to function like real kidneys without triggering the immune rejection that often complicates traditional transplants. Researchers at Mayo Clinic and other institutions are using 3D bioprinters to create living tissue models from medical imaging and patient-specific cells, allowing scientists to study disease progression and test treatments before moving to human trials. According to current timelines, these artificial kidneys could become available as soon as 2030.

The potential impact is enormous. More than 90,000 people are currently on the waiting list for a kidney transplant in the United States, yet only about 1 in 3 people waiting received a transplant last year. Lab-grown kidneys could dramatically expand the supply of organs available for transplantation and eliminate the years-long waits that patients currently endure.

How Are Clinical Trials Being Redesigned to Move Faster?

Beyond organ engineering, artificial intelligence is playing a critical role in accelerating how kidney disease research moves from concept to patient care. One example is the ASSENT initiative, which brings together researchers, patients, clinicians, and regulators to improve clinical trials for Alport syndrome, a rare genetic kidney disease. The initiative uses AI to analyze global patient data and identify measurements that can predict disease progression earlier, potentially speeding up research on targeted treatments.

This data-driven approach represents a shift away from traditional trial design, where researchers often wait years to see whether a treatment slows disease. By using AI to spot early warning signs of kidney damage or disease progression, researchers can design shorter, more efficient trials that still provide meaningful evidence of whether a drug works.

Steps to Stay Informed About New Kidney Disease Treatments

• Talk to Your Care Team: Many new treatments are still in clinical trials or recently approved, so discussing your specific situation with your doctor is essential to understand which options may be right for you.
• Monitor FDA Approvals: Keep track of breakthrough status designations and FDA approvals for kidney disease therapies, as these signal treatments that could improve patient outcomes and may become available soon.
• Review Plain-Language Summaries: Organizations like the American Kidney Fund publish plain-language summaries of clinical trial results, designed to help patients understand what researchers found without needing to read technical journal articles.
• Join Patient Communities: Connecting with other people living with kidney disease can help you learn about emerging treatments and clinical trials that may be recruiting participants in your area.

What New Medicines Are Showing Promise for Kidney Protection?

Several medications originally developed for other conditions are now being studied for their ability to slow kidney disease progression. Tirzepatide, a diabetes medicine that targets two gut hormone pathways to regulate blood sugar, was found in the SURPASS trials to be associated with lower levels of albuminuria, or protein in the urine, in people with type 2 diabetes. This finding suggests that diabetes medications may offer dual benefits: controlling blood sugar while also protecting kidney health.

Dapagliflozin, an SGLT2 inhibitor originally used for diabetes, has emerged as particularly promising. Recent research suggests it may significantly slow CKD progression and could delay kidney failure by approximately 6 to 7 years compared to standard treatment. This means some patients could avoid or postpone the need for dialysis or kidney transplant for years longer. Dapagliflozin is now being studied in children with Alport syndrome and in patients with autosomal dominant polycystic kidney disease (ADPKD) to determine whether it can slow kidney function loss and cyst growth.

The FDA has also approved injectable semaglutide to help reduce the risk of CKD worsening, kidney failure, and death in adults with type 2 diabetes and CKD. Originally developed to help manage blood sugar, research now shows it may also protect kidney health in some patients.

How Is Technology Improving Transplant Outcomes?

For patients who do receive kidney transplants, new technologies are improving both the availability and success of these procedures. The Room Temperature Machine Perfusion (RTMP) device represents a significant advance in organ preservation. Many donated kidneys are not used today because they can be damaged during storage and transport. The RTMP device keeps kidneys healthy longer and allows doctors to test how well they function before surgery, potentially expanding the pool of usable organs. The FDA recently granted the device breakthrough status, which accelerates the regulatory review process for technologies that could meaningfully improve patient care.

Clinical trials are also testing new approaches to prevent complications after transplant. The AWAKE study is a Phase 3 trial examining whether ravulizumab can reduce delayed graft function (DGF), a condition where a transplanted kidney does not start working immediately after surgery. Preventing or reducing DGF could help transplant recipients avoid dialysis soon after surgery and reach independence from dialysis sooner.

Another trial, called TRANSCEND, is testing felzartamab in transplant recipients who develop late antibody-mediated rejection (AMR), a serious immune response that can damage the transplanted kidney. Because AMR has limited standardized treatment options and can threaten long-term transplant survival, this research addresses a critical gap in post-transplant care.

What Treatments Are Emerging for Specific Kidney Conditions?

Beyond general kidney protection, researchers are developing targeted therapies for specific kidney diseases and complications. Break Wave lithotripsy is a new non-invasive treatment for kidney stones that uses low-pressure ultrasound waves to break stones into smaller pieces that may pass more easily. In the SOUND trial, the treatment met its main safety and effectiveness goals, and patients did not require anesthesia. This innovation could allow some people with kidney stones to receive treatment in an office setting rather than undergoing surgery.

For other conditions, several medicines are in development or under regulatory review:

• Dotinurad for Gout: This newer medicine helps the kidneys remove more uric acid from the body and is already approved in Japan and China; research is ongoing to determine whether it could become an option for managing gout and high uric acid levels in other countries.
• Veverimer for Metabolic Acidosis: An oral medicine being studied in the Phase 3 REVIVE trial for adults with CKD and metabolic acidosis, a condition where too much acid builds up in the body; it is designed to help remove acid and raise bicarbonate levels.
• Vadadustat for Anemia: A recent study shows this oral medication, taken once daily, is just as effective as injectable treatments for managing anemia in dialysis patients, offering patients a simpler treatment option.
• Oxylanthanum Carbonate for High Phosphate Levels: A potential new treatment currently under FDA review for patients receiving dialysis; it works as a phosphate binder that prevents phosphate in food from being absorbed into the bloodstream.

The convergence of regenerative medicine, artificial intelligence, and targeted drug development is creating a new era in kidney disease treatment. While many of these innovations are still in clinical trials, the pace of progress suggests that patients with kidney disease will soon have more options for slowing disease progression, avoiding transplant complications, and potentially accessing lab-grown organs that could eliminate the transplant waiting list entirely.